Effect of tenofovir on didanosine absorption in patients with HIV

Annals of Pharmacotherapy

Volumn 37, Issue 9, 2003, Pages 1325-1328

  Fulco, Patricia Pecora ^a,b   Kirian, Margaret A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Didanosine; Interaction; Pharmacokinetic; Tenofovir

Indexed keywords

DIDANOSINE; GANCICLOVIR; NEVIRAPINE; PROTEINASE INHIBITOR; TENOFOVIR; VALGANCICLOVIR;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EXCRETION; ENTERIC COATED TABLET; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL SOCIETY; MEDLINE; PANCREATITIS; PARAMETER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TABLET FORMULATION;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CLINICAL TRIALS; DIDANOSINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS;

EID: 0041422326     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C412     Document Type: Review

References (21)

1. Schwetz BA. New drug for HIV-1 infection. JAMA 2001;286:2660.
2. Thompson CA. Prodrug of tenofovir diphosphate approved for combination HIV therapy. Am J Health Syst Pharm 2002;59:18.
3. Department of Health and Human Services, the Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. www.hivatis.org (accessed 2002 Sept 17).
4. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM. et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002;288:222-35.
5. Edder M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29.
6. Package insert. Viread (tenofovir DF). Foster City, CA: Gilead Sciences, October 2001.
7. Barditch-Crove P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
8. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-63.
9. Staszewski S, Gallant J, Pozniak A, Suleiman JMAH, DeJesus E, Sayre J, et al. Efficacy and safety of tenofovir DF vs. stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary results (poster 564b). Presented at: The 10th Conference of Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003.
10. Kearney BP, Flaherty J, Wolf J, Barriere S, Wong S, Chen SS, et al. Coadministration of tenofovir DF and didanosine: a pharmacokinetic and safety evaluation (poster 172). Presented at: The 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, October 28-31, 2001.
11. Kearney BP, Damle B, Plummer A, Sayre J, Namini H, Ryan K, et al. Pharmacokinetic evaluation of tenofovir DF and enteric-coated didanosine (poster 9026). Presented at: The 14th International AIDS Conference, Barcelona, July 7-12, 2002.
12. Pecora Fulco P, Higginson R, Orenstein R. Acute pancreatitis associated with the concurrent use of valganciclovir and didanosine (abstract B 10396). The 14th International AIDS Conference, Barcelona, July 7-12, 2002.
13. Cimoch PJ, Lavelle J, Pollard R, Gaines Griffy K, Wong R. Tarnowski TL, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:227-34.
14. Kearney BP. Isaacson E, Sayre J, Plummer A, Cheng A. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction (poster 533). Presented at: The 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003.
15. Negredo E, Ribera E, Viciana P, Pedrol E, Miralles C, Galindo MJ, et al. QD multicenter study: simplification therapy with once-daily NVP + DDI + TDF (tenofovir) (abstract). Presented at: The 14th International AIDS Conference, Barcelona, July 7-12, 2002.
16. van Leth F, Hassink E, Phanuphak P. Miller S, Gazzard B, Cahn P, et al. Results of the 2NN Study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (abstract 176). Presented at: The 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003.
17. Package insert. Videx EC (didanosine). Princeton, NJ: Bristol-Myers Squibb, January 2002.
18. Knupp C, Damle B, Nichola P, Kaul S. Bioequivalence of two formulations of didanosine (ddl), enteric coated and the chewable tablet in healthy volunteers and subjects infected with HIV (abstract 1664). Presented at: The 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000.
19. Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, et al. Long-term toxicity/activity profile of 2′,3′ dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336:526-9.
20. Yarchoan R, Mitsuya H, Pluda JM, Marczyk KS, Thomas RV. Hartman NR, et al. The National Cancer Institute Phase I study of 2′,3′-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis 1990;12(suppl 5):S522-33.
21. Kearney BP, Liaw S, Yale K, Hayashi S, Namini H, Wolk JJ, et al. Pharmacokinetics following single dose administration of tenofovir DF in subjects with renal impairment. Presented at: The Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, November 17-21, 2002.